This is a standard non-deal roadshow schedule with no material information. No trading action warranted. Monitor for any subsequent 6-K filings that may contain earnings results or business updates from these meetings.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $13.60entry
- T+1 · 6mo ago −1.10%α −0.45% · $13.45
- T+5 · 6mo ago +1.10%α −0.52% · $13.75
- T+20 · 5mo ago −2.21%α −3.79% · $13.30
- T+60 · 3mo ago −8.90%α −13.75% · $12.39
Price Chart
How similar events traded
Executive Summary
Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May 20 to June 3, 2026, hosted by Elara Capital, Bank of America, Nomura, and Investec across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton. This is a routine disclosure of non-deal roadshow activity with no material financial information, guidance, or operational updates.
Key Facts
- Management will participate in investor meetings from May 20 to June 3, 2026
- Meetings hosted by Elara Capital, Bank of America, Nomura, and Investec
- All meetings are in-person group meetings across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton
- No financial results, guidance, or material business updates were disclosed
Financial Impact
No financial figures disclosed, routine investor relations activity with no quantifiable impact
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000339 |
| Document: 0001575872-26-000339-index.html | 0001575872-26-000339 |
| Document: 0001575872-26-000339.txt | 0001575872-26-000339 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers